Immunohistochemical assay for MUM-1 (Multiple Myeloma Oncogene 1/IRF4) aims to detect this nuclear transcription factor expressed in activated B lymphocytes and in the terminal stages of B cell differentiation (plasma cells). It is primarily used to classify diffuse large B-cell lymphoma (DLBCL) into two subtypes: an activated B-cell (ABC) subtype that is MUM-1 positive, and a follicular activated B-cell (GCB) subtype that is usually MUM-1 negative.